SK Chemicals

TheraVida, SK Chemicals to develop THVD-201 and THVD-202 for OAB, UUI

Wednesday, April 3, 2013

TheraVida, a biopharmaceutical company based in Mountain View, Calif., and South Korea-based SK Chemicals have signed a license agreement for two of TheraVida’s proprietary combination drug product candidates, THVD-201 and THVD-202. The agreement grants SK Chemicals exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). 

[Read More]